Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Trial results for MDxHealth's Bevacizumab published in New England Journal of Medicine


Tuesday, 4 Mar 2014 02:00am EST 

MDxHealth SA:Publication in the New England Journal of Medicine of a phase III randomized trial of bevacizumab, brand name Avastin, for newly diagnosed glioblastoma patients, confirms the clinical utility of the company's PredictMDx for Glioblastoma test.PredictMDx for Glioblastoma (MGMT) test, included in the 2013 National Comprehensive Cancer Network (NCCN) Senior Adult Oncology Guidelines, provides actionable information to oncologists seeking to provide personalized treatment of elderly patients with glioblastoma (GBM).Test assesses the methylation status of the MGMT gene, which is a key DNA repair component.Studies on thousands of clinical trial patients have demonstrated that PredictMDx for Glioblastoma can help oncologists identify newly diagnosed glioblastoma patients that are likely to respond to the most commonly used class of brain cancer drugs (alkylating agents). 

Company Quote

3.5
-0.11 -3.05%
11:35am EDT